Salicylate acutely stimulates 5'-AMP-activated protein kinase and insulin-independent glucose transport in rat skeletal muscles.

Author(s)
Serizawa, Yasuhiro; Oshima, Rieko; Yoshida, Mitsuki; Sakon, Ichika; Kitani, Kazuto; Goto, Ayumi; Tsuda, Satoshi; Hayashi, Tatsuya

Citation
Biochemical and biophysical research communications (2014), 453(1): 81-85

Issue Date
2014-10-10

URL
http://hdl.handle.net/2433/192273

© 2014 Elsevier Inc.; This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。

Type
Journal Article
Salicylate acutely stimulates 5′-AMP-activated protein kinase and insulin-independent glucose transport in rat skeletal muscles

Yasuhiro Serizawa, Rieko Oshima*, Mitsuki Yoshida, Ichika Sakon, Kazuto Kitani, Ayumi Goto, Satoshi Tsuda, Tatsuya Hayashi

Laboratory of Sports and Exercise Medicine, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, 606-8501, Japan

*Address correspondence to:
Rieko Oshima, M.S.
Laboratory of Sports and Exercise Medicine, Graduate School of Human and Environmental Studies, Kyoto University, Yoshida-nihonmatsu-cho, Sakyo-ku, Kyoto, 606-8501, Japan
Telephone, Fax: +81-75-753-6640, E-mail: oshima.rieko.37r@st.kyoto-u.ac.jp

E-mail: tatsuya@kuhp.kyoto-u.ac.jp (T. Hayashi)
ABSTRACT

Salicylate (SAL) has been recently implicated in the antidiabetic effect in humans. We assessed whether 5′-AMP-activated protein kinase (AMPK) in skeletal muscle is involved in the effect of SAL on glucose homeostasis. Rat fast-twitch epitrochlearis and slow-twitch soleus muscles were incubated in buffer containing SAL. Intracellular concentrations of SAL increased rapidly (<5 min) in both skeletal muscles, and the Thr172 phosphorylation of the α subunit of AMPK increased in a dose- and time-dependent manner. SAL increased both AMPKα1 and AMPKα2 activities. These increases in enzyme activity were accompanied by an increase in the activity of 3-O-methyl-D-glucose transport, and decreases in ATP, phosphocreatine, and glycogen contents. SAL did not change the phosphorylation of insulin receptor signaling including insulin receptor substrate 1, Akt, and p70 ribosomal protein S6 kinase. These results suggest that SAL may be transported into skeletal muscle and may stimulate AMPK and glucose transport via energy deprivation in multiple muscle types. Skeletal muscle AMPK might be part of the mechanism responsible for the metabolic improvement induced by SAL.

Keywords: Salicylate, 5′-AMP-activated protein kinase, Glucose transport, Insulin signaling, Skeletal muscle, Diabetes mellitus

Abbreviations:
SAL, salicylate; T2D, type 2 diabetes mellitus; AMPK, 5′-AMP-activated protein kinase; KRB, Krebs–Ringer bicarbonate buffer; DNP, 2,4-dinitrophenol; AICAR: 5-aminimidazole-4-carboxamide-1-α-D-ribonucleoside; IRS1, insulin receptor substrate 1; p70S6K, p70 ribosomal protein S6 kinase; GLUT4, glucose transporter 4; AMPKα1, α1-containing AMPK complex; AMPKα2, α2-containing AMPK complex; 3MG, 3-O-methyl-D-glucose; PCr, phosphocreatine; SE, standard error.
1. Introduction

Salicylate (SAL), a willow bark product, has been used as an anti-inflammatory agent since ancient times. SAL induces systemic anti-inflammatory effects by suppressing cyclooxygenase, resulting in decreased production of proinflammatory mediators such as prostaglandins [1].

Interestingly, a number of clinical studies have suggested that SAL stimulates metabolic processes and improves glucose homeostasis in humans. Goldfine et al [2] demonstrated that a 14-week oral SAL treatment (salsalate 3.0–4.0 g/day) significantly improved glycemic control in patients with type 2 diabetes (T2D). The mean changes in the hemoglobin A1c level were $-0.36\%$ at 3.0 g/day, $-0.34\%$ at 3.5 g/day, and $-0.49\%$ at 4.0 g/day compared with the placebo. More recently, Goldfine et al [3] demonstrated that long-term (48 weeks) oral SAL treatment (salsalate 3.5 g/day) significantly improved glycemic control in people with T2D. The mean hemoglobin A1c level after 48 weeks was $0.37\%$ lower in the SAL group than in the placebo group.

We hypothesized that 5'-AMP-activated protein kinase (AMPK) in skeletal muscle plays a pivotal role in the antidiabetic effect of SAL. AMPK is a metabolite-sensing protein kinase and is acutely activated by energy-depriving stimuli in skeletal muscle such as exercise (contraction). Although Hawley et al [4] first reported that AMPK is phosphorylated in mouse soleus muscle 90 min after an intraperitoneal injection of SAL, to our
knowledge, no study has provide fundamental evidence of AMPK activation in skeletal muscle. Thus, the primary aim of the current study was to determine whether SAL is taken up into skeletal muscle cells and, if so, whether it stimulates AMPK by altering the energy status. We examined two different types of isolated rat skeletal muscles: fast-glycolytic epitrochlearis [5] and slow-oxidative soleus muscles [6].
2. Materials and Methods

2.1. Animals

Male Sprague Dawley rats weighing 150 g (Shimizu Breeding Laboratories, Kyoto, Japan) fed a standard chow and water *ad libitum* were randomly divided into experimental groups after an overnight fast. The experimental protocols were approved by Kyoto University Graduate School of Human and Environmental Studies, and Kyoto University Radioisotope Research Center.

2.2. Muscle preparation in vitro

Muscle incubation was conducted as we have previously described [7]. Epitrochlearis and soleus muscles were isolated after cervical dislocation. The muscles were attached to an incubation apparatus and preincubated in Krebs-Ringer bicarbonate buffer (KRB) containing 2 mM pyruvate for 40 min. Muscles were then transferred to buffer containing various concentrations (0–10 mM) of SAL (sodium salicylate) for 30 min or buffer containing 5 mM SAL for up to 60 min. Muscles were also incubated in buffer containing 0.5 mM 2,4-dinitrophenol (DNP) for 10 min or 2 mM 5-aminoimidazole-4-carboxamide-1-α-D-ribonucleoside (AICAR) for 30 min for maximal stimulation of AMPK, or 1 μM insulin for 30 min for maximal stimulation of insulin signaling. The muscles samples were either used for SAL transport and glucose transport measurements, or they were frozen in
liquid nitrogen for other assays.

2.3. Western blotting

Western blot analysis was performed as we have previously described [7]. Frozen muscle was homogenized in buffer containing 1% Triton X-100, 20 mM Tris·HCl (pH 7.4), 250 mM sucrose, 50 mM NaCl, 2 mM dithiothreitol, 50 mM NaF, 5 mM sodium pyrophosphate, 50 mg/l trypsin inhibitor, 4 mg/l leupeptin, 0.1 mM benzamidine, 0.5 mM phenylmethylsulfonyl fluoride, and 1 mM Na$_2$VO$_4$ (Buffer A) at 4°C. The homogenate was centrifuged at 16,000 $g$ for 40 min at 4°C. Aliquots of the supernatant (10 µg of protein) were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was blocked with skim milk and then incubated overnight at 4°C with primary antibodies. The primary antibodies were to AMPK $\alpha$ subunit (#2532; Cell Signaling Technology, Danvers, MA, USA), phosphospecific AMPK $\alpha$ subunit Thr$^{172}$ (#2531; Cell Signaling Technology), phosphospecific insulin receptor substrate 1 (IRS1) Tyr$^{612}$ (44-816G, Life Technologies, Carlsbad, CA, USA), IRS1 (06-248, Millipore, Billerica, MA, USA), phosphospecific Akt Ser$^{473}$ (#9271; Cell Signaling Technology), Akt (#9272, Cell Signaling Technology), phosphospecific p70 ribosomal protein S6 kinase (p70S6K) Thr$^{389}$ (#9205, Cell Signaling Technology), p70S6K (#9202, Cell Signaling Technology), glucose transporter 4 (GLUT4) (4670-1704, Biogenesis, Poole, UK), and actin (#4968, Cell Signaling Technology). The membrane was then incubated with anti-rabbit IgG. Protein signals were
developed using enhanced chemiluminescence (Millipore) and detected with ImageCapture G3 (Liponics, Tokyo, Japan).

2.4. Isoform-specific AMPK activity assay

AMPK comprises the catalytic $\alpha$ and regulatory $\beta$ and $\gamma$ subunits, and there are two distinct $\alpha$ subunits: $\alpha1$ and $\alpha2$ [8]. The kinase activities of $\alpha1$-containing AMPK complex (AMPK$\alpha1$) and $\alpha2$-containing AMPK complex (AMPK$\alpha2$) were measured as we have previously described [7]. Frozen muscles were homogenized in Buffer A, and the resultant supernatants (100 $\mu$g protein) were incubated with either anti-$\alpha1$ or -$\alpha2$ antibody [7] and Protein A Sepharose beads (Amersham Biosciences, Uppsala, Sweden) at 4°C overnight. The beads were subjected to the kinase reaction using the SAMS peptide as a substrate. The kinase activity was expressed as incorporated ATP per min per immunoprecipitated protein.

2.5. SAL transport and glucose transport assay

SAL transport was measured using the double-isotope ([7-14C]salicylic acid and D-[1-3H(N)]mannitol) method. Muscles were preincubated and then incubated in KRB containing 5 mM [7-14C]salicylic acid (0.3 $\mu$Ci/ml, American Radiolabeled Chemicals, St. Louis, MO) and 1 mM D-[1-3H(N)]mannitol (1.5 $\mu$Ci/ml, American Radiolabeled Chemicals) at 37°C for up to 15 min. Muscles were then incubated in 1 M NaOH at 80°C for 10 min. Digestates were neutralized with 1 M HCl, centrifuged at 20,000 g for 3
min, and the radioactivity in the supernatant was measured by a scintillation counter. The intracellular space was determined as described [9], and the intracellular SAL concentration was calculated. 3-\(^{\text{\textit{O}}\text{-}}\)Methyl-\(\text{D}\)-glucose (3MG) transport was measured using the double-isotope ([\(^{3}\text{H}\)3MG and \(\text{D}\)-[1-\(^{14}\text{C}\)]mannitol) method, as we have previously described [7]. The transport activity was expressed as 3MG taken up per intracellular space per hour.

2.6.\(\text{ATP, phosphocreatine (PCr), and glycogen assay}\)

ATP and PCr contents were measured enzymatically as we have described previously [10]. Glycogen content was measured using a glucose assay reagent (Glucose CII Test, Wako, Osaka, Japan) as we have previously described [11].

2.7.\(\text{Statistical analysis}\)

Data are expressed as mean ± standard error (SE). Differences between two groups were compared with Student’s \(t\) test. Multiple means were analyzed using one-way ANOVA followed by \textit{post hoc} comparison with Tukey’s or Dunnett’s test. \(P < 0.05\) was considered significant.
3. **Results**

3.1. **Effects of SAL on AMPK α subunit Thr\(^{172}\) phosphorylation and AMPK activity in skeletal muscles**

The Thr\(^{172}\) residue of the α subunit is the stimulatory phosphorylation site of AMPK [12]. We examined the phosphorylation status in both muscles. The dose-response study of AMPK phosphorylation showed significant increases by 2.4- and 2.7-fold in epitrochlearis muscle at concentrations of 5 and 10 mM of SAL (30 min), and by 1.5-, 2.1-, and 2.2-fold in soleus muscle at concentrations of 1, 5, and 10 mM of SAL (30 min), respectively (Fig. 1A). The time-course study showed that 5 mM of SAL significantly phosphorylated AMPK after as little as 5 min in soleus and 15 min in epitrochlearis muscles (Fig. 1B). SAL did not change the total amount of AMPK. SAL (5 mM, 30 min) increased the activity of both AMPKα\(_1\) and AMPKα\(_2\) by 4.1- and 3.6-fold in epitrochlearis muscle, and by 2.1- and 2.4-fold in soleus, respectively (Fig. 1C).

3.2. **SAL uptake in skeletal muscles**

To our knowledge, no study has shown that SAL is taken up into skeletal muscle tissue. We found that the intracellular concentration of SAL increased rapidly in both epitrochlearis and soleus muscles in a time-dependent manner (Fig. 2A). The intracellular concentration of SAL was 3.1 ± 0.2 mM in epitrochlearis and 1.8 ± 0.1 mM in soleus at 15 min after
the start of exposure to buffer containing 5 mM SAL.

3.3. Effects of SAL on glucose transport and energy status in skeletal muscles

AMPK is thought to act as a signaling molecule leading to an increase in insulin-independent glucose transport elicited by energy-depriving stresses in skeletal muscle [13,14]. The increased AMPK activity by SAL (5 mM, 30 min) was associated with a 2.7-fold increase in 3MG transport in epitrochlearis muscle and a 4.2-fold increase in soleus muscle (Fig. 2B) compared with the basal conditions. Correspondingly, the contents of ATP, PCr, and glycogen were significantly lower in SAL-treated muscle samples than in the basal muscle samples for both epitrochlearis and soleus (Table 1).

3.4. Effects of SAL on insulin signaling molecules in skeletal muscles

The pharmacological inhibitor of oxidative phosphorylation, DNP, significantly phosphorylated AMPK in both muscles (Fig. 2C). The AMPK activator AICAR strongly phosphorylated AMPK in epitrochlearis and slightly phosphorylated AMPK in soleus, as we have previously reported [15]. By contrast, insulin did not phosphorylate AMPK in either muscle. Similar to DNP and AICAR, SAL did not increase the phosphorylation of insulin signaling molecules including IRS1, Akt, and p70S6K. SAL did not affect GLUT4 or actin content in either muscle.
4. Discussion

It has been suggested that skeletal muscle AMPK is involved in a variety of acute and chronic metabolic activation processes [16,17,18,19] such as insulin-independent glucose transport, fatty acid oxidation, glycogen regulation, expression of the GLUT4 glucose transporter, stimulation of peroxisome proliferator-activated receptor γ coactivator 1α, mitochondrial biogenesis, and enhanced insulin sensitivity. Besides exercise (contraction), there are a number of physiologically relevant stimuli of skeletal muscle AMPK, such as adipokines including leptin and adiponectin, antidiabetic drugs such as metformin and thiazolidinediones, and functional foods and their natural components [18,20,21]. In our earlier studies, we demonstrated that Morus alba leaf extract [22], caffeine [10], berberine [15], Coptidis rhizoma extract [23], and caffeic acid [24], all of which have been implicated as having antidiabetic properties, acutely (<30 min) promoted AMPK activity in isolated rat skeletal muscles.

SAL has been shown to uncouple oxidative phosphorylation [1,25]. The SAL-induced decrease in ATP concentration has been documented in *Drosophila melanogaster* tissue culture (SL2) cells [26] and human neutrophils [27]. However, as far as we know, the present study is the first to demonstrate the ability of SAL to decrease the energy status in skeletal muscle. Interestingly, Hawley et al [4] showed that SAL is a direct AMPK activator that binds to the same site as the synthetic AMPK activator A-769662, which causes allosteric AMPK activation and inhibition of
dephosphorylation of the α subunit Thr^{172}. They also demonstrated that SAL promoted AMPK phosphorylation and activity in the absence of energy deprivation (an increase in ADP: ATP ratio) in HEK-293 cells [4]. Thus, SAL may stimulate AMPK via both energy-dependent and energy-independent processes in skeletal muscle.

Hawley et al [4] found that oral SAL treatment for 2 weeks decreased fasting glucose concentration and improved insulin sensitivity and glucose tolerance in both the wild-type and AMPK β1 subunit knockout mice in a high fat diet-induced insulin-resistant condition. This seems to suggest that the effect of SAL on glucose metabolism is AMPK independent. However, Western blot analysis of rat tissues has revealed that the β1 subunit is most abundant in the liver and that little exists in skeletal muscle, whereas the β2 subunit is most abundant in skeletal muscle and little exists in the liver [28]. In fact, the β1-knockout mice had decreased AMPK activity in the liver but not in skeletal muscle [29]. Therefore, it is still possible that skeletal muscle AMPK plays an important role in mediating the effects of SAL on glucose homeostasis.

The typical plasma concentration of SAL for clinical use is 0.95–1.9 mM, but the plasma concentration of free SAL falls in the range of <0.25 mM because of plasma protein binding of 80–90% [1]. Although we showed that the intracellular concentration of SAL increased rapidly after exposure to SAL (Fig. 2A), it is unlikely that a single oral dose of SAL is enough to induce substantial metabolic activation in skeletal muscle. As speculated from the
finding of Goldfine et al [2] who demonstrated improved glycemic control after a 14-week SAL treatment in people with T2D, repeated SAL administration might contribute to a clinically relevant activation of AMPK in skeletal muscle.

An advantage of using an isolated muscle preparation is that we could eliminate the confounding effects elicited by systemic administration of SAL. In particular, we considered the possibility that SAL inhibits IKKβ, an enzyme that is responsible for the activation of nuclear factor κ [30], and that evokes direct and/or indirect metabolic changes in skeletal muscle [31]. We used Western blotting to examine the inhibitory effect of SAL on IKKα/β phosphorylation in isolated muscles. However, because of the very low phosphorylation in the basal samples, we could not determine whether IKK phosphorylation decreased after SAL treatment in either muscle (data not shown).

In summary, we report here for the first time that SAL was transported into muscle cells, where it increased both AMPKα1 and α2 activities, and glucose transport, and decreased muscle energy status. These effects occurred in both fast- and slow-twitch skeletal muscles. We propose that skeletal muscle AMPK is involved in the mechanism leading to the SAL-induced activation of glucose metabolism.
Author contributions

YS, RO and TH designed the experiments; YS, RO, MY, IS, KK, AG and ST performed experiments; YS and RO analyzed data; YS, RO and TH wrote the manuscript.

Grants

This study was supported by research grants from the Japan Society for the Promotion of Science (TH, 23617009), Urakami Foundation for Food and Food Culture (TH), the Foundation for Dietary Scientific Research (TH), and Asahi Group Foundation (TH), Vascular Disease Research Foundation (TH), and Research Fellowship of the Japan Society for the Promotion of Science for Young Scientists (AG, ST).

Conflict of Interest

The authors state no conflict of interest.

Acknowledgments

We are grateful to the Kyoto University Research Center for Low Temperature and Materials Sciences and the Radioisotope Research Center
of Kyoto University for their support. We thank Licht Miyamoto and Tatsuro Egawa for valuable discussion.
Figure and table legends

Fig. 1 SAL phosphorylates the α subunit Thr^{172}, and stimulates both AMPKα1 and AMPKα2 activities in skeletal muscles.

(A) Epitrochlearis (EPI) and soleus (SOL) muscles were incubated with SAL (0–10 mM) for 30 min. The lysate was analyzed by Western blotting. Values are means ± SE; n = 6. **P < 0.01 vs. basal condition. Representative immunoblots are shown. (B) Muscles were incubated in the absence (basal) or presence of 5 mM SAL for 0–60 min. The lysate was analyzed by Western blotting. n = 6–10. **P < 0.01 and *P < 0.05 vs. basal. Representative immunoblots are shown. (C) Muscles were incubated with or without SAL (5 mM) for 30 min, and α-isoform-specific AMPK activity was measured. Values are means ± SE; n = 6. ** P < 0.01 vs. basal condition.

Fig. 2 SAL is transported into isolated skeletal muscles and stimulates 3MG transport without affecting insulin signaling in skeletal muscles.

(A) Muscles were incubated with 5 mM SAL for 0–15 min. Intracellular SAL concentration was measured at each time point. Values are means ± SE; n = 6–7. ** P < 0.01 vs. 0-min group. ## P < 0.01 vs. 5-min group. (B) Muscles were incubated with or without SAL (5 mM) for 30 min, and 3MG transport was measured. Values are means ± SE; n = 8–9. ** P < 0.01 vs. basal condition. (C) Muscles were incubated with or without SAL (5 mM) for 30 min, AICAR (2 mM) or insulin (1 µM) for 30 min, or DNP (0.5 mM) for 10 min, and
analyzed by Western blotting. Representative immunoblots are shown.

Table 1

SAL decreases the energy status in skeletal muscles.

Muscles were incubated with or without 5 mM SAL for 30 min. ATP, PCr, and glycogen contents were measured. Values are expressed as nmol/mg wet weight. Values are means ± SE; n = 5. ** P < 0.01 vs. basal condition.
References


[31] M. Yuan, N. Konstantopoulos, J. Lee, L. Hansen, Z.W. Li, M. Karin, S.E. Shoelson,
Figure 1.
Figure 2.
<table>
<thead>
<tr>
<th></th>
<th>Basal</th>
<th>SAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epitrochlearis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATP</td>
<td>4.4±0.2</td>
<td>2.3±0.3**</td>
</tr>
<tr>
<td>PCr</td>
<td>17.2±0.7</td>
<td>9.7±0.9**</td>
</tr>
<tr>
<td>glycogen</td>
<td>19.1±0.8</td>
<td>12.0±1.1**</td>
</tr>
<tr>
<td>Soleus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATP</td>
<td>2.0±0.2</td>
<td>1.0±0.1**</td>
</tr>
<tr>
<td>PCr</td>
<td>7.6±0.9</td>
<td>2.5±0.4**</td>
</tr>
<tr>
<td>glycogen</td>
<td>11.7±0.3</td>
<td>5.9±0.4**</td>
</tr>
</tbody>
</table>